The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study.
paper
Cited
Public
Unavailable
- Authors
- Jetly, Rakesh; Heber, Alexandra; Fraser, George; Boisvert, Denis
- Year
- 2015
- Journal
- Psychoneuroendocrinology
- PMID
- 25467221
- DOI
- 10.1016/j.psyneuen.2014.11.002
OBJECTIVE: Investigate the efficacy of nabilone capsules (NAB) in reducing the frequency and intensity of nightmares in subjects with PTSD. PATIENTS AND METHODS: Canadian male military personnel with PTSD, who despite standard treatment continued to experience trauma-related nightmares, received double-blind treatment with 0.5mg NAB or placebo (PBO), and then titrated to the effective dose (nightmare suppression) or reaching a maximum of 3.0mg. Subjects were followed for 7 weeks and then, following a 2-week washout period, were titrated with the other study treatment and followed for an additional 7 weeks. The modified intent-to-treat (mITT) population, which included all treated subjects that met inclusion/exclusion criteria, was analyzed. RESULTS: Ten subjects were included in the mITT population. The mean reduction in nightmares as measured by the CAPS Recurring and Distressing Dream scores were -3.6 Β± 2.4 and -1.0 Β± 2.1 in the NAB and PBO groups, respectively (p=0.03). Mean global improvement as measured by the Clinical Global Impression of Change (CGI-C) was 1.9 Β± 1.1 (i.e. much improved) and 3.2 Β± 1.2 (i.e. minimally improved) in the NAB and PBO groups, respectively (p=0.05) Five out of 10 (50%) were much improved on NAB versus 1 out of 9 (11%) on PBO. Results for the General Well Being Questionnaire (WBQ) were 20.8 Β± 22 and -0.4 Β± 20.6 in the NAB and PBO groups, respectively (p=0.04). The proportion of subjects who experienced a treatment-related occurrence of adverse events was 50% in the NBO group and 60% in the PBO group. No event was severe nor resulted in a drop-out. This study is registered with Health Canada. CONCLUSION: In this small sample NAB provided significant relief for military personnel with PTSD, indicating that it shows promise as a clinically-relevant treatment for patients with nightmares and a history of non-response to traditional therapies. These findings need to be replicated in a larger cohort. There is a need for further exploration of the effect of nabilone on other symptoms of PTSD such as re-experiencing, hyper vigilance and insomnia.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Acute and chronic cannabis vapor exposure produces immediate and delayed impacts on phases of fear learning in a sex specific manner. | Lightfoot SHM et al. | β | 2026 | β |
| Cannabis and Mental Health: A Review. | Kansagara D et al. | β | 2026 | β |
| New treatments for OCD? Evidence for cannabinoids and psychedelics. | Van Ameringen M et al. | β | 2026 | β |
| Targeting CXCL8 in post-traumatic stress disorder and Alzheimer's disease: insights from cross-disorder molecular analysis. | Liao D et al. | β | 2026 | β |
| The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety. | Lyndon S | β | 2026 | β |
| Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. | Botsford SL et al. | β | 2025 | β |
| Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis. | Raminelli AO et al. | β | 2025 | β |
| Endorsement of: "Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper" by the World Sleep Society. | Provini F et al. | β | 2025 | β |
| Feasibility and Tolerability of Nabilone for the Treatment of Obesity: A Randomized Controlled Pilot Trial. | Matheson J et al. | β | 2025 | β |
| Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort. | Steeger CM et al. | β | 2025 | β |
| Frequent recreational cannabis use and its association with caries and severe tooth loss: Findings from the National Health and Nutrition Examination Survey, 2015-2018. | Clonan E et al. | β | 2025 | β |
| MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review. | Stanicic F et al. | β | 2025 | β |
| Medicinal cannabis in the management of anxiety disorders: A systematic review. | Roberts L et al. | β | 2025 | β |
| Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine. | Dodds C et al. | β | 2025 | β |
| Psychotherapeutic, pharmacological and other active interventions from the NICE guideline for post-traumatic stress disorder with sleep disorder: systematic review and meta-analysis. | Zhao YF et al. | β | 2025 | β |
| The differential effects of medicinal cannabis on mental health: A systematic review. | de Bode N et al. | β | 2025 | β |
| UK medical cannabis registry: A clinical outcome analysis of medical cannabis therapy in chronic pain patients with and without co-morbid sleep impairment. | Datta I et al. | β | 2025 | β |
| Understanding the Role of Endocannabinoids in Posttraumatic Stress Disorder. | Ney L | β | 2025 | β |
| Afraid and Awake: The Interaction Between Trauma and Sleep in Children and Adolescents. | Fellman V et al. | β | 2024 | β |
| [Cannabinoid Drugs in the Treatment of Psychiatric Disorders - Data from the German Federal Institute for Drugs and Medical Devices]. | WΓΌlfing F et al. | β | 2024 | β |
| Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials. | D'Angelo M et al. | β | 2024 | β |
| Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. | MΓΌller-Vahl KR | β | 2024 | β |
| [Cannabis use and cannabis use disorders]. | Hoch E et al. | β | 2024 | β |
| CBD's potential impact on Parkinson's disease: An updated overview. | Hafida EG et al. | β | 2024 | β |
| Divergent input patterns to the central lateral amygdala play a duet in fear memory formation. | Gao JH et al. | β | 2024 | β |
| Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review. | Rice LJ et al. | β | 2024 | β |
| Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis. | SabΓ© M et al. | β | 2024 | β |
| Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence. | Lynskey MT et al. | β | 2024 | β |
| Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. | Sippel LM et al. | β | 2024 | β |
| [Pharmacological treatment of posttraumatic stress disorder]. | Roepke S et al. | β | 2024 | β |
| Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. | Huang CY et al. | β | 2024 | β |
| The Use of Compounds Derived from <i>Cannabis sativa</i> in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders. | StasiΕowicz-KrzemieΕ A et al. | β | 2024 | β |
| Thoughtfully Integrating Cannabis Products Into Chronic Pain Treatment. | Boehnke KF et al. | β | 2024 | β |
| Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. | Burback L et al. | β | 2024 | β |
| Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine. | Nouh RA et al. | β | 2024 | β |
| Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. | Singewald N et al. | β | 2023 | β |
| A Prospective Comparison of Bipolar I and II Subjects with and without Comorbid Cannabis Use Disorders from the COGA Dataset. | Preuss UW et al. | β | 2023 | β |
| Cannabis and Cannabinoids for Pain and Posttraumatic Stress Disorder in Military Personnel and Veterans. | Wolfgang AS et al. | β | 2023 | β |
| Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review. | Amaral C et al. | β | 2023 | β |
| Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report. | Ragnhildstveit A et al. | β | 2023 | β |
| [Cannabis use in adolescents : Narrative Review and Position paper of the "Addiction Disorders in Adolescents" task force of the Austrian Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ΓGKJP)]. | Skala K et al. | β | 2023 | β |
| Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective. | Ney LJ et al. | β | 2023 | β |
| Circulating endocannabinoids and psychological outcomes in women with PTSD. | Botsford C et al. | β | 2023 | β |
| Do trauma cue exposure and/or PTSD symptom severity intensify selective approach bias toward cannabis cues in regular cannabis users with trauma histories? | DeGrace S et al. | β | 2023 | β |
| Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. | Hasbi A et al. | β | 2023 | β |
| Enhancing Psychological Interventions for Post-Traumatic Stress Disorder (PTSD) Treatment with Memory Influencing Drugs. | Marchetta E et al. | β | 2023 | β |
| Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study. | Vaddiparti K et al. | β | 2023 | β |
| Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. | Cairns EA et al. | β | 2023 | β |
| Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression. | De Feo G et al. | β | 2023 | β |
| Perceived Risks and Therapeutic Benefits of Cannabis Among College Students Amidst the COVID-19 Pandemic. | Espinoza S et al. | β | 2023 | β |
| Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. | Fagan HA et al. | β | 2023 | β |
| Phytochemical interventions for post-traumatic stress disorder: A cluster co-occurrence network analysis using CiteSpace. | Gao B et al. | β | 2023 | β |
| THC and CBD: Similarities and differences between siblings. | Stella N | β | 2023 | β |
| Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial). | Roepke S et al. | β | 2023 | β |
| Acute sleep interventions as an avenue for treatment of trauma-associated disorders. | Swift KM et al. | β | 2022 | β |
| A Systematic Review of Medical Cannabinoids Dosing in Human. | Campos DA et al. | β | 2022 | β |
| Cannabinoid use is enhanced by stress and changes conditioned stress responses. | Hodebourg R et al. | β | 2022 | β |
| Cannabis dosing and administration for sleep: a systematic review. | Velzeboer R et al. | β | 2022 | β |
| Clinical Approaches to Cannabis: A Narrative Review. | Slawek DE et al. | β | 2022 | β |
| Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists. | Monti JM et al. | β | 2022 | β |
| [Comorbidity of posttraumatic stress disorder and addiction from a biopsychosocial perspective]. | Kapfhammer HP | β | 2022 | β |
| Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. | Laudanski K et al. | β | 2022 | β |
| Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. | Raut SB et al. | β | 2022 | β |
| Drugs Used in Parasomnia. | Proserpio P et al. | β | 2022 | β |
| Effects of Cannabis on PTSD Recovery: Review of the Literature and Clinical Insights. | Bedard-Gilligan M et al. | β | 2022 | β |
| Efficacy and acceptability of psychotherapeutic and pharmacological interventions for trauma-related nightmares: A systematic review and network meta-analysis. | Zhang Y et al. | β | 2022 | β |
| Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD. | Murkar A et al. | β | 2022 | β |
| Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far. | Maddison KJ et al. | β | 2022 | β |
| Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. | Bilbao A et al. | β | 2022 | β |
| Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. | AminiLari M et al. | β | 2022 | β |
| Medical cannabis for treatment-resistant combat PTSD. | Nacasch N et al. | β | 2022 | β |
| Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. | Geldenhuys C et al. | β | 2022 | β |
| Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study. | Sznitman SR et al. | β | 2022 | β |
| Pro- and anti-inflammatory cytokines Interleukin-6 and Interleukin-10 predict therapy outcome of female patients with posttraumatic stress disorder. | Renner V et al. | β | 2022 | β |
| Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. | Hill KP et al. | β | 2022 | β |
| The Construct of Medical and Non-Medical Marijuana-Critical Review. | Silczuk A et al. | β | 2022 | β |
| The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials. | Skeie-Larsen M et al. | β | 2022 | β |
| The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier? | Mohamed A et al. | β | 2022 | β |
| The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. | Bonn-Miller MO et al. | β | 2022 | β |
| Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. | Legare CA et al. | β | 2022 | β |
| The role of the immune system in posttraumatic stress disorder. | Katrinli S et al. | β | 2022 | β |
| The Synthetic Cannabinoid WIN55,212-2 Can Disrupt the Golgi Apparatus Independent of Cannabinoid Receptor-1. | Lott J et al. | β | 2022 | β |
| Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next? | Ney LJ et al. | β | 2022 | β |
| Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness? | Tibbo PG et al. | β | 2021 | β |
| Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology. | Brucki SMD et al. | β | 2021 | β |
| Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety. | Murkar A et al. | β | 2021 | β |
| Cannabis in the management of PTSD: a systematic review. | Rehman Y et al. | β | 2021 | β |
| Cannabis use and posttraumatic stress disorder comorbidity: Epidemiology, biology and the potential for novel treatment approaches. | Kondev V et al. | β | 2021 | β |
| Changes in cannabis use, exposure, and health perceptions following legalization of adult recreational cannabis use in California: a prospective observational study. | Gali K et al. | β | 2021 | β |
| Constituents of Cannabis Sativa. | Rock EM et al. | β | 2021 | β |
| Do Adolescent Exposure to Cannabinoids and Early Adverse Experience Interact to Increase the Risk of Psychiatric Disorders: Evidence from Rodent Models. | Portugalov A et al. | β | 2021 | β |
| Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. | Kaul M et al. | β | 2021 | β |
| Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review. | Steardo L et al. | β | 2021 | β |
| Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada. | Cahill SP et al. | β | 2021 | β |
| Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. | Stanciu CN et al. | β | 2021 | β |
| Exercise-induced increases in Anandamide and BDNF during extinction consolidation contribute to reduced threat following reinstatement: Preliminary evidence from a randomized controlled trial. | Crombie KM et al. | β | 2021 | β |
| High-Titer Production of Olivetolic Acid and Analogs in Engineered Fungal Host Using a Nonplant Biosynthetic Pathway. | Okorafor IC et al. | β | 2021 | β |
| Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19? | Khalid S et al. | β | 2021 | β |
| Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. | Hoskins MD et al. | β | 2021 | β |
| Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. | McKee KA et al. | β | 2021 | β |
| PTSD: Past, present and future implications for China. | Zhou YG et al. | β | 2021 | β |
| Sleep management in posttraumatic stress disorder: a systematic review and meta-analysis. | Maher AR et al. | β | 2021 | β |
| Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. | Ponte L et al. | β | 2021 | β |
| The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. | Bonn-Miller MO et al. | β | 2021 | β |
| Use of cannabinoids for the treatment of patients with post-traumatic stress disorder. | Forsythe ML et al. | β | 2021 | β |
| Cannabinoids as therapeutics for PTSD. | Sbarski B et al. | β | 2020 | β |
| Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. | Suraev AS et al. | β | 2020 | β |
| Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. | Botsford SL et al. | β | 2020 | β |
| Cannabis and Complex Posttraumatic Stress Disorder: A Narrative Review With Considerations of Benefits and Harms. | Dagan Y et al. | β | 2020 | β |
| Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. | Inglet S et al. | β | 2020 | β |
| Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians. | Lake S et al. | β | 2020 | β |
| Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders. | Siclari F et al. | β | 2020 | β |
| Drugs Used in Parasomnia. | Proserpio P et al. | β | 2020 | β |
| Effects of β<sup>9</sup>-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies. | Raymundi AM et al. | β | 2020 | β |
| Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder. | Vimalanathan A et al. | β | 2020 | β |
| Endocannabinoid System Components as Potential Biomarkers in Psychiatry. | Navarrete F et al. | β | 2020 | β |
| Interventions for adults with a history of complex traumatic events: the INCiTE mixed-methods systematic review. | Melton H et al. | β | 2020 | β |
| Meet Your Stress Management Professionals: The Endocannabinoids. | deRoon-Cassini TA et al. | β | 2020 | β |
| Nightmares and the Cannabinoids. | Mamelak M | β | 2020 | β |
| Possible therapeutic applications of cannabis in the neuropsychopharmacology field. | FernΓ‘ndez-Ruiz J et al. | β | 2020 | β |
| Reviewing the Potential of Psychedelics for the Treatment of PTSD. | Krediet E et al. | β | 2020 | β |
| Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder. | LaFrance EM et al. | β | 2020 | β |
| "Sparks that became a little light over time":Β A qualitative investigation of musicking as a means of coping in adults with PTSD. | Ophir I et al. | β | 2020 | β |
| The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review. | Hindocha C et al. | β | 2020 | β |
| Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. | Sholler DJ et al. | β | 2020 | β |
| A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis. | Loflin MJE et al. | β | 2019 | β |
| Cannabinoid interventions for PTSD: Where to next? | Ney LJ et al. | β | 2019 | β |
| Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. | Black N et al. | β | 2019 | β |
| Cannabis and mental illness: a review. | Lowe DJE et al. | β | 2019 | β |
| Cannabis: A potential efficacious intervention for PTSD or simply snake oil? | Abizaid A et al. | β | 2019 | β |
| Cannabis industry and medical cannabis clinics need regulation. | Kahan M et al. | β | 2019 | β |
| Clinical Therapeutic Strategy and Neuronal Mechanism Underlying Post-Traumatic Stress Disorder (PTSD). | Yabuki Y et al. | β | 2019 | β |
| Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. | Sloan ME et al. | β | 2019 | β |
| Glucocorticoid-induced enhancement of extinction-from animal models to clinical trials. | de Quervain D et al. | β | 2019 | β |
| How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. | Hoch E et al. | β | 2019 | β |
| Inflammation and post-traumatic stress disorder. | Hori H et al. | β | 2019 | β |
| Medical Cannabis for the Primary Care Physician. | Slawek D et al. | β | 2019 | β |
| Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. | Dos Santos RG et al. | β | 2019 | β |
| Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. | Sartori SB et al. | β | 2019 | β |
| Recent advances in the neurobiology of posttraumatic stress disorder: A review of possible mechanisms underlying an effective pharmacotherapy. | Malikowska-Racia N et al. | β | 2019 | β |
| RΓ©glementer lβindustrie du cannabis et les cliniques de cannabis mΓ©dical : Une nΓ©cessitΓ©. | Kahan M et al. | β | 2019 | β |
| Skin Conductance as a Viable Alternative for Closing the Deep Brain Stimulation Loop in Neuropsychiatric Disorders. | Wickramasuriya DS et al. | β | 2019 | β |
| The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? | Kayser RR et al. | β | 2019 | β |
| Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. | Orsolini L et al. | β | 2019 | β |
| Addictive potential of novel treatments for refractory depression and anxiety. | Kolar D | β | 2018 | β |
| A review of medical marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or just high hopes? | Shishko I et al. | β | 2018 | β |
| A Review of the Neurobiological Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach. | Lanius RA et al. | β | 2018 | β |
| Cannabis regulatory science: risk-benefit considerations for mental disorders. | Borodovsky JT et al. | β | 2018 | β |
| Chronic exposure to cannabinoids before an emotional trauma may have negative effects on emotional function. | Sbarski B et al. | β | 2018 | β |
| Diminished positive affect and traumatic stress: A biobehavioral review and commentary on trauma affective neuroscience. | Fonzo GA | β | 2018 | β |
| Drugs Used in Parasomnia. | Proserpio P et al. | β | 2018 | β |
| Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats. | Morena M et al. | β | 2018 | β |
| Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. | Hill MN et al. | β | 2018 | β |
| Management of nightmares in patients with posttraumatic stress disorder: current perspectives. | El-Solh AA | β | 2018 | β |
| Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013. | Waltman SH et al. | β | 2018 | β |
| Medical Use of Cannabinoids. | Fraguas-SΓ‘nchez AI et al. | β | 2018 | β |
| Medicinal versus Recreational Cannabis Use among Returning Veterans. | Metrik J et al. | β | 2018 | β |
| Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. | Ney LJ et al. | β | 2018 | β |
| Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper. | Morgenthaler TI et al. | β | 2018 | β |
| Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. | Fattore L et al. | β | 2018 | β |
| Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder. | Crombie KM et al. | β | 2018 | β |
| Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. | Cooper ZD et al. | β | 2018 | β |
| Single-Prolonged Stress: A Review of Two Decades of Progress in a Rodent Model of Post-traumatic Stress Disorder. | Lisieski MJ et al. | β | 2018 | β |
| Sleep Disorders in Patients With Posttraumatic Stress Disorder. | El-Solh AA et al. | β | 2018 | β |
| The impact of PTSD clusters on cannabis use in a racially diverse trauma-exposed sample: An analysis from ecological momentary assessment. | Buckner JD et al. | β | 2018 | β |
| Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. | Mouhamed Y et al. | β | 2018 | β |
| Therapeutic Symptomatic Strategies in the Parasomnias. | Manni R et al. | β | 2018 | β |
| The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. | Abrams DI | β | 2018 | β |
| Weighing the Benefits and Risks of Medical Marijuana Use: A Brief Review. | Karst A | β | 2018 | β |
| A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. | Lim K et al. | β | 2017 | β |
| Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. | O'Neil ME et al. | β | 2017 | β |
| Cannabinoids as therapeutic for PTSD. | Loflin MJ et al. | β | 2017 | β |
| Cannabis, Cannabinoids, and Sleep: a Review of the Literature. | Babson KA et al. | β | 2017 | β |
| Genome to Phenome: A Systems Biology Approach to PTSD Using an Animal Model. | Chakraborty N et al. | β | 2017 | β |
| Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? | Turna J et al. | β | 2017 | β |
| Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review. | Steenkamp MM et al. | β | 2017 | β |
| Medical Cannabinoids in Children and Adolescents: A Systematic Review. | Wong SS et al. | β | 2017 | β |
| Regulation of fear extinction by long-term depression: The roles of endocannabinoids and brain derived neurotrophic factor. | Bennett MR et al. | β | 2017 | β |
| Sleep in PTSD: Conceptual model and novel directions in brain-based research and interventions. | Germain A et al. | β | 2017 | β |
| Stress, glucocorticoids and memory: implications for treating fear-related disorders. | de Quervain D et al. | β | 2017 | β |
| The Endocannabinoid System and Anxiety. | Lisboa SF et al. | β | 2017 | β |
| The endocannabinoid system as a target for novel anxiolytic drugs. | Patel S et al. | β | 2017 | β |
| Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. | Mizrachi Zer-Aviv T et al. | β | 2016 | β |
| Developmental regulation of fear learning and anxiety behavior by endocannabinoids. | Lee TT et al. | β | 2016 | β |
| Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. | Haney M et al. | β | 2016 | β |
| Endocannabinoid concentrations in hair are associated with PTSD symptom severity. | Wilker S et al. | β | 2016 | β |
| Impaired Ethanol-Induced Sensitization and Decreased Cannabinoid Receptor-1 in a Model of Posttraumatic Stress Disorder. | Matchynski-Franks JJ et al. | β | 2016 | β |
| Marijuana Legalization: Impact on Physicians and Public Health. | Wilkinson ST et al. | β | 2016 | β |
| Targeting the Endocannabinoid System in Psychiatric Illness. | Katzman MA et al. | β | 2016 | β |
| The 2013 Canadian Forces Mental Health Survey: Background and Methods. | Zamorski MA et al. | β | 2016 | β |
| The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings. | Berardi A et al. | β | 2016 | β |
| Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. | Koek RJ et al. | β | 2016 | β |
| Investigational drugs under development for the treatment of PTSD. | Ragen BJ et al. | β | 2015 | β |
| Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. | Belendiuk KA et al. | β | 2015 | β |
| Post-traumatic stress disorder. | Yehuda R et al. | β | 2015 | β |